(Reuters) - Celsion Corp said a late-stage study of its experimental liver cancer treatment ThermoDox did not meet the main goal of increasing patients' survival without their cancer worsening.
The study, named HEAT, was designed to show a 33 percent improvement in progression-free survival, Celsion said in a statement.
Celsion CEO Michael Tardugno said the company is conducting additional analyses of data from the trial to assess the future strategic value of ThermoDox.
(Reporting By Pallavi Ail in Bangalore; Editing by Roshni Menon)
Source: http://news.yahoo.com/celsions-liver-cancer-therapy-fails-meet-stage-trial-123207408--finance.html
orcl the hartford illinois primary 2012 michael bay zsa zsa gabor illinois primary trayvon martin 911 call
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.